Sugi Predict

Sugi Predict / Compounds / SCHEMBL4328697

SCHEMBL4328697

SCHEMBL4328697

O=C(O)c1ccc(CC(=O)c2ccccn2)cc1

nearest known ligand 0.55

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 2/20 0.55
▸ NAPRT Q6XQN6 1/20 0.55
▸ P4HTM Q9NXG6 1/20 0.55
▸ L3MBTL1 Q9Y468 1/20 0.55
▸ SRD5A2 P31213 2/20 0.54
▸ POLB P06746 1/20 0.54
▸ KMT2A Q03164 2/20 0.50
▸ ALDH1A1 P00352 2/20 0.49
▸ KDM4E B2RXH2 1/20 0.49
▸ HPGD P15428 1/20 0.49
▸ HSD17B10 Q99714 1/20 0.49
▸ CES2 O00748 1/20 0.47
▸ CES1 P23141 1/20 0.47
▸ SMN1; SMN2 Q16637 1/20 0.46
▸ PKM P14618 1/20 0.46
▸ CTNNB1 P35222 3/20 0.44
▸ WNT3A P56704 2/20 0.44
▸ GRM4 Q14833 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1515752 0.88 LMNA (0.59) LMNANAPRTP4HTML3MBTL1POLB
SCHEMBL38664624 0.82 NPC1 (0.60) LMNANAPRTP4HTML3MBTL1KMT2A
SCHEMBL38664275 0.82 RAB9A (0.54) LMNANAPRTP4HTML3MBTL1KMT2A
SCHEMBL4870832 0.82 RAB9A (0.54) LMNANAPRTP4HTML3MBTL1KMT2A
SCHEMBL4323055 0.82 PKM (0.69) LMNAPOLBKMT2AALDH1A1KDM4E
SCHEMBL5228758 0.81 CES2 (0.52) LMNANAPRTP4HTML3MBTL1KMT2A
SCHEMBL6176980 0.79 ALOX5 (0.56) LMNAP4HTMSRD5A2ALDH1A1SMN1; SMN2
SCHEMBL38661938 0.78 SMN1; SMN2 (0.63) LMNAL3MBTL1KMT2AALDH1A1KDM4E
SCHEMBL5237903 0.78 TLR7 (0.57) L3MBTL1KMT2AALDH1A1CES2CES1
SCHEMBL5232062 0.78 SMN1; SMN2 (0.63) LMNAL3MBTL1KMT2AALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7566781-B2 Imidazopyridine compound BANYU PHARMACEUTICAL CO., LTD. (JP) 2009-07-28 — — US disclosed
US-20070249659-A1 melanin concentrating hormone receptor antagonist; preventing or treating vascular system diseases, nervous system disorders, metabolic disorders, urogenital diseases, respiratory diseases disorders; N-(2-ethyl-3-methylimidazo[1,2-a]pyridin-6-yl)-3-fluoro-4-(pyridin-2-ylmethoxy)benzamide BANYU PHARMACEUTICAL., LTD. (JP) 2007-10-25 — — US disclosed
EP-1748048-A1 IMIDAZOPYRIDINE COMPOUND BANYU PHARMACEUTICAL CO., LTD. (JP) 2007-01-31 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070249659-A1 melanin concentrating hormone receptor antagonist; preventing or treating vascular system diseases, nervous system disorders, metabolic disorders, urogenital diseases, respiratory diseases disorders; N-(2-ethyl-3-methylimidazo[1,2-a]pyridin-6-yl)-3-fluoro-4-(pyridin-2-ylmethoxy)benzamide MC1R, MCHR2, MCHR1 LMNA 3634/4885NAPRT 3168/4885P4HTM 220/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.